Showing 6841-6850 of 10228 results for "".
- ASDS: Percentage of Us Wanting Cosmetic Surgery Doubled Since 2013https://practicaldermatology.com/news/asds-percentage-of-us-wanting-cosmetic-surgery-doubled-since-2013/2458141/Nearly 70 percent of consumers now say they are thinking about getting a cosmetic treatment, according to survey data released by the American Society for Dermatologic Surgery (ASDS). The ASDS Consumer
- Sciton Rewards Consumer in New Sweepstakeshttps://practicaldermatology.com/news/sciton-rewards-consumer-in-new-sweepstakes/2458143/Consumers can win $1,000 towards one of several Sciton treatments including Halo, BBL, Contour TRL, and diVa Laser Vaginal Therapy as part of an ongoing national sweepstakes. The Sciton consumer sweepstakes runs through August 23, with one w
- FDA Approves New Antibiotic for Skin Infectionshttps://practicaldermatology.com/news/fda-approves-new-antibiotic-for-skin-infections/2458149/The FDA has approved Melinta Therapeutics' Baxdela (delafloxacin) for adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathog
- Study Findings Cast Doubt on Link Between Eczema and Cardiovascular Diseasehttps://practicaldermatology.com/news/study-findings-cast-doubt-on-link-between-eczema-and-cardiovascular-disease/2458151/Despite recent findings to the contrary, a new study in the British Journal of Dermatology has found that eczema is likely not associated with an increase in cardiovascular risk factors or diseases. "In our study, people who reported having atopic dermatitis were not at any
- Some Hair Products May Up Breast Cancer Risk in Certain Womenhttps://practicaldermatology.com/news/some-hair-products-may-up-breast-cancer-risk-in-some-women/2458156/Use of hair dyes may increase risk for breast cancer among certain women, new research suggests. Specifically, dark brown or black hair dye was associated with a 51 percent increased overall risk of developing breast cancer among African American women, and a 72 percent increased risk of
- Coppertone Whips Up Excitement About New Sunscreen Linehttps://practicaldermatology.com/news/coppertone-whips-up-excitement-about-new-sunscreen-line/2458152/Coppertone is going all out to launch their new Whipped line, available in both CLEARLYSheer® and WaterBABIES® Pure & Simple formulas, including partnering with beauty influencers and the Skin Cancer Foundation. The brand is promot
- FDA Cracks Down on Sonar For Distributing Unapproved Derm Drugshttps://practicaldermatology.com/news/fda-cracks-down-on-sonar-for-distributing-unapproved-derm-drugs/2458153/U.S. District Judge Kathleen M. Williams for the Southern District of Florida entered a consent decree of permanent injunction between the United States and Stratus Pharmaceuticals Inc. of Miami, Florida, Sonar Products Inc. of Carlstadt, New Jersey an
- Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studieshttps://practicaldermatology.com/news/tildrakizumab-performs-well-in-two-phase-3-psoriasis-studies/2458164/Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients
- Game Change: New Handheld Tissue Scanner Can See Below Surface of Skin in Psoriasishttps://practicaldermatology.com/news/game-change-new-handheld-tissue-scanner-looks-below-surface-of-skin-in-psoriasis/2458166/A new handheld tissue scanner allows dermatologists to look below the surface of skin in psoriasis patients and can provide clinically relevant information, such as the structure of skin layers and blood vessels, without the need for contrast agents or radiation exposure. A team of r
- First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/first-patient-enrolled-in-delivers-study-of-diacerein-1-ointment-for-ebs/2458168/The first patient has enrolled in Castle Creek Pharmaceuticals (CCP) Phase 2/3 DELIVERS clinical trial evaluating the safety and efficacy of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bull